Demant A/S
CSE:DEMANT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
209.6
293.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Demant A/S
Demant A/S, an eminent player in the world of hearing healthcare, finds its roots in Denmark, where it was founded in 1904. The journey, sparked by the compassion of founder Hans Demant who sought ways to improve his wife's hearing experience, has evolved into a global operation focused on improving quality of life through innovative hearing solutions. Demant transcends beyond traditional hearing aids, carving a niche in providing a broad range of hearing healthcare services. These include audiometric equipment, hearing implants, diagnostic instruments, and personal communication applications, all aligned with the mission to help people overcome communication barriers. Key to Demant's strategy is its strong emphasis on research and development, ensuring that it remains at the forefront of technological advancements in audiology.
The company monetizes its operations through a combination of cutting-edge product sales and a suite of ancillary services that cater to different segments of the hearing healthcare market. Leveraging a robust distribution network, Demant ensures a wide market reach, with offerings meticulously tailored to meet regional consumer needs. Collaborations with retailers, hospitals, and clinics across the globe amplify its market penetration, driving both revenue and brand loyalty. Additionally, Demant taps into the growing demand for auditory digital health solutions, offering cloud-based services that integrate seamlessly into consumer lifestyles. This multifaceted approach not only diversifies revenue streams but also fortifies Demant's standing as a holistic hearing solutions provider, underpinned by a commitment to enhancing living through auditory wellness.
Demant A/S, an eminent player in the world of hearing healthcare, finds its roots in Denmark, where it was founded in 1904. The journey, sparked by the compassion of founder Hans Demant who sought ways to improve his wife's hearing experience, has evolved into a global operation focused on improving quality of life through innovative hearing solutions. Demant transcends beyond traditional hearing aids, carving a niche in providing a broad range of hearing healthcare services. These include audiometric equipment, hearing implants, diagnostic instruments, and personal communication applications, all aligned with the mission to help people overcome communication barriers. Key to Demant's strategy is its strong emphasis on research and development, ensuring that it remains at the forefront of technological advancements in audiology.
The company monetizes its operations through a combination of cutting-edge product sales and a suite of ancillary services that cater to different segments of the hearing healthcare market. Leveraging a robust distribution network, Demant ensures a wide market reach, with offerings meticulously tailored to meet regional consumer needs. Collaborations with retailers, hospitals, and clinics across the globe amplify its market penetration, driving both revenue and brand loyalty. Additionally, Demant taps into the growing demand for auditory digital health solutions, offering cloud-based services that integrate seamlessly into consumer lifestyles. This multifaceted approach not only diversifies revenue streams but also fortifies Demant's standing as a holistic hearing solutions provider, underpinned by a commitment to enhancing living through auditory wellness.
Strong Results: Demant delivered strong H1 performance, with organic growth of 13% and record-high EBIT, mainly driven by hearing aids and recent product launches.
Upgraded Guidance: The company raised its full-year organic growth outlook to 11–14% (from 6–10%) and upgraded EBIT guidance to DKK 4–4.4 billion.
Hearing Healthcare Outperformance: Hearing Healthcare segment saw 15% organic growth and a 28% increase in EBIT, with robust market share gains and positive momentum across key markets.
Communications Weakness: Communications segment underperformed with negative organic growth of 15% and a greater EBIT loss than last year, due to weak demand in both gaming and enterprise.
Gross Margin Headwinds: Gross margin declined 1.3 ppts due to adverse FX effects, high inventory costs, and promotions in gaming, but is expected to improve in the second half.
Sustainability Progress: The company achieved approval of its science-based emissions targets and increased renewable energy use to 22%.
Cash Flow & Leverage: Operating cash flow was strong at nearly DKK 1.9 billion, improving leverage and enabling potential share buybacks.